Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Galvanize Therapeutics has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in September 2025.
Galvanize Therapeutics's investors include Norwest, Sofinnova Partners, Janus Henderson Investors, Ally Bridge Group, Fidelity.
Galvanize Therapeutics is headquartered in San Carlos, United States.
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Galvanize Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Galvanize Therapeutics — Funding & Investors." VCBacked, September 3, 2025, https://www.vcbacked.co/company/galvanize-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Galvanize Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/galvanize-therapeutics
{{cite web |title=Galvanize Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/galvanize-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated